Heterocyclic Compound For Inducing Degradation Of Mutant Kras Protein

< Back

Heterocyclic Compound For Inducing Degradation Of Mutant Kras Protein

Abstract: Provided is a compound useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer. The present inventors carried out investigations with regard to compounds useful as an active ingredient in a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compound represented by formula (I) has an excellent action with regard to inducing the degradation of mutant KRAS protein and particularly with regard to inducing the degradation of G12V mutant, G12D mutant, and G12C mutant KRAS proteins, and has a mutant KRAS inhibitory activity and particularly G12V mutant, G12D mutant, and G12C mutant KRAS inhibitory activities. The present invention was achieved on the basis of these findings. The heterocyclic compound according to the present invention or a salt thereof can be used as a therapeutic agent for pancreatic cancer.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #

Filing Date

25 February 2025

Publication Number

10/2025

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ASTELLAS PHARMA INC.

5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Inventors

1. MORIKAWA, Takahiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

2. IMADA, Sunao

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

3. HAMAGUCHI, Hisao

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

4. OKUMURA, Mitsuaki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

5. IMAIZUMI, Tomoyoshi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

6. KOGANEMARU, Yohei

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

7. HONJO, Eriko

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

8. FUJIWARA, Yuta

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

9. KAWAMINAMI, Eiji

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

10. YOSHINARI, Tomohiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

11. ISHIOKA, Hiroki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

12. KURAMOTO, Kazuyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

13. NISHIZONO, Yoshihiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Specification

Documents

Application Documents

#	Name	Date
1	202547016301-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [25-02-2025(online)].pdf	2025-02-25
2	202547016301-STATEMENT OF UNDERTAKING (FORM 3) [25-02-2025(online)].pdf	2025-02-25
3	202547016301-REQUEST FOR EXAMINATION (FORM-18) [25-02-2025(online)].pdf	2025-02-25
4	202547016301-PROOF OF RIGHT [25-02-2025(online)].pdf	2025-02-25
5	202547016301-PRIORITY DOCUMENTS [25-02-2025(online)].pdf	2025-02-25
6	202547016301-FORM 18 [25-02-2025(online)].pdf	2025-02-25
7	202547016301-FORM 1 [25-02-2025(online)].pdf	2025-02-25
8	202547016301-DECLARATION OF INVENTORSHIP (FORM 5) [25-02-2025(online)].pdf	2025-02-25
9	202547016301-COMPLETE SPECIFICATION [25-02-2025(online)].pdf	2025-02-25
10	202547016301-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [25-02-2025(online)].pdf	2025-02-25
11	202547016301-FORM-26 [26-02-2025(online)].pdf	2025-02-26
12	202547016301-FORM 3 [04-08-2025(online)].pdf	2025-08-04